Compare Natera Inc. Common Stock (NTRA) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Xylem, Inc. — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Xylem, Inc. trades at $103.66 (market cap $23.99B). The key difference: Natera Inc. Common Stock is far larger — about 2.4× Xylem, Inc.'s market cap, and Xylem, Inc. pays a 1.67% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Xylem, Inc. for 51 Days on average.
| NTRA | XYL | |
|---|---|---|
Market Cap | $57.03B | $23.99B |
Volume | 1,131,157 | 2,429,384 |
Sector | Health | Industrials |
52-Week High | $425.64 | $152.95 |
52-Week Low | $179.42 | $100.92 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $56.18B | $25.77B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Xylem (XYL) trades at $102.54, down slightly by 0.05% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results due October 27, 2026. Revenue has grown from $5.5B in 2022 to $9.04B in 2025, with net income margins improving to 10.59%. Recent developments include a $1.5B senior note offering to fund acquisitions of Cornell Pump and Roper Pump, alongside a new CFO appointment.
The outlook is supported by steady revenue growth, margin expansion, and strategic acquisitions in water technology, though near-term sentiment is cautious due to technical weakness and China-related headwinds. Risks include execution of acquisitions and debt increase, but analyst consensus price target of $146.63 implies significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
